INDIANAPOLIS, Sept. 24 /PRNewswire-FirstCall/ -- Today Eli Lilly and
Company (NYSE: LLY) announced that it is set to become the first
pharmaceutical research company to disclose its payments to physicians in the
At a speech before the Economic Club of Indiana today, Lilly's president
and chief executive officer, John Lechleiter, Ph.D., outlined the company's
plans to launch an online registry of physician payments in 2009. Lechleiter
announced the physician registry as a part of a broader outline on the
company's transformation efforts.
"With each of our industry firsts, from launching our clinical trials
registry to the public reporting of educational grants, Lilly is striving to
be a leader in improving transparency across our industry," said Lechleiter.
"As Lilly continues to look for more ways to be open and transparent about our
business, we've learned that letting people see for themselves what we're
doing is the best way to build trust."
Earlier this year, Lilly was the first pharmaceutical research company to
endorse bipartisan federal legislation - known as the Physician Payments
Sunshine Act - that would establish a national registry of payments to
physicians by medical device, medical supply and pharmaceutical companies.
The legislation, which was introduced by United States Senators Charles
Grassley (R-Iowa) and Herbert Kohl (D-Wisconsin) last September, has not been
passed yet by Congress.
Lechleiter added, "Though we remain hopeful that the Sunshine Act will be
passed by Congress at some point, Lilly is taking action independently. Being
more transparent by opening up our business to the public is an important step
to building trust and confidence."
Under the Lilly registry plan, the public will have access to an Internet
database listing its payments to physicians. Lilly will launch this registry
as early as the second half of 2009. When first launched, its contents will
include 2009 payments to physicians who serve the company as speakers and
advisors. By 2011, Lilly plans to expand the reporting capabilities of the
registry to resemble the Sunshine Act legislation. The registry will be
updated annually to reflect the previous year's payment information.
"Eli Lilly is leading the charge for transparency in the relationship
between pharmaceutical companies and doctors by fulfilling the obligations of
the Physician Payments Sunshine Act before it has been enacted," said Senator
Kohl. "It takes a lot of courage to be the first. They have made a
principled decision that I believe will benefit both their business and the
consumers of their products."
"Lilly is proud of the important and longstanding relationships we have
with physicians," said Lechleiter. "Many physicians perform valuable services
for the biopharmaceutical industry by advising us on the development of new
medicines and giving lectures to other medical professionals to educate them
about new treatment options. For these services, they are compensated at
market rates. These services help to advance the science related to medicines
and are important to both current and future patients who rely on
pharmaceuticals as an integral part of their therapy."
"Our primary focus is the well-being of our patients and APA has adopted
strict disclosure policies to ensure our patients are informed regarding
relationships between physicians and industry," said James H. Scully Jr.,
M.D., CEO and Medical Director of the American Psychiatric Association. "We
applaud efforts by Lilly to ensure there is transparency in their
relationships with physicians."
Lilly's plan to create a physicians payments registry is consistent with
other voluntary actions it has taken recently to enhance transparency in
health care, including its support of the Physician Payments Sunshine Act. In
2004, Lilly became the first company to voluntarily make public its clinical
trials and its clinical trials data; that information can be found at
www.lillytrials.com. Last year Lilly added another first by publicly
reporting all of its educational grants and charitable contributions and, each
quarter, posting the data online at www.lillygrantoffice.com.
Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of first-in-class and best-in-class pharmaceutical products by
applying the latest research from its own worldwide laboratories and from
collaborations with eminent scientific organizations. Headquartered in
Indianapolis, Ind., Lilly provides answers - through medicines and information
- for some of the world's most urgent medical needs. Additional information
about Lilly is available at www.lilly.com. C-LLY
SOURCE Eli Lilly and Company